Veracyte Inc. (VCYT) 12-Month Stock Forecast & Price Target Cone

VCYT scores 74 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The score is built from five pillars:

• Fundamental Cash Engine (14 / 20): Per the RQD rating, ROIC is 4.6% and FCF yield is 3.02%. This pillar is middling. Returns on invested capital are modest relative to the stock's valuation multiples, so the cash-generation case is supportive but not the strongest part of the thesis.
• Whale 13F Flow (17 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the highest-scoring pillar, suggesting institutional interest is a meaningful component of the current rating. The holders section, however, contains no 13F detail, so the underlying flow cannot be independently examined here.
• Insider Conviction (11 / 20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, indicating weaker insider-conviction signals than the other components.
• Macro Regime Fit (14 / 20): Per the RQD rating, beta is 1.08 and the pillar reflects sector sensitivity. A beta slightly above 1 implies the stock has moved modestly more than the broad market, so it may amplify market direction in either direction.
• Forensic Balance Sheet (18 / 20): Per the RQD rating, Altman Z is 26, Piotroski F is 9/9, and Debt/Equity is 0.03. This is the strongest pillar and points to a low-leverage, financially robust profile.

Taken together, the rating suggests a balance-sheet-strong, institutionally supported name whose valuation (see Snapshot) is demanding relative to current returns and whose insider signals are the weakest link. Upside drivers in the source data are the forensic strength and institutional flow; the principal valuation tradeoff is the elevated P/E against a 4.6% ROIC. This is an analytical framing, not personalized advice.

Veracyte Inc. (VCYT) is a NASDAQ-listed issuer in the Health Care sector, Medical Specialities industry..2B.

Revenue rose from $361.1M in FY 2023 to $517.1M in FY 2025, and operating income moved from a loss to $57.8M over the same span. Per the market data, the gross margin is 70.1%, operating margin 11.2%, and net margin 12.8%, with ROIC at 4.6%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 9/9; Debt/Equity is 0.03. Debt declined from $539.8M in FY 2023 to $43.4M in FY 2025, consistent with the forensic balance-sheet score.

• 🐂 Primary Bull Case: Forensic balance sheet is strong (Altman Z 26, Piotroski F 9/9, Debt/Equity 0.03) and debt fell from $539.8M to $43.4M over FY 2023–FY 2025. With Fundamental Cash Engine at 14/20 (ROIC 4.6%, FCF yield 3.02%) and Institutional Whale Flow at 16/20, sustained execution supports upside toward the top of the $29.45 – $60.91 52-week range.
• 🐻 Primary Bear Case: Valuation is demanding at 63.2 P/E (TTM) and 58.7 EV/EBITDA against a 4.6% ROIC and weak insider-conviction pillar (11/20). Investors must weigh 63.2x trailing P/E and 58.7x EV/EBITDA against 11.2% operating margins and a 1.08 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore —

• Key Question #1: What specific products and customer segments drive the $517.1M FY 2025 revenue, and how much is recurring?
• Key Question #2: What explains the swing from a -$74.4M net loss in FY 2023 to $66.4M net income in FY 2025, and how much is durable?
• Key Question #3: What do the 13F institutional filings and insider Form 4 transactions actually show, given the holders data is empty?